Exchange: NASDAQ·Updated 07:53 PM EDT
News
all
press releases
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.
Zacks
More News
Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates
Madrigal (MDGL) delivered earnings and revenue surprises of +21.96% and +4.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
Corcept (CORT) delivered earnings and revenue surprises of +1,000.00% and +18.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.
Stocktwits
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug
Madrigal Pharmaceuticals announced earlier on Friday that it has received three new U.S. patents for its lead drug, Rezdiffra.
Stocktwits
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH PR Newswire SUZHOU, China and MLNDAL, Sweden, July 1, 2026 SUZHOU, China and MLNDAL, Sweden, July 1, 2026 /PRNewswire...
PR Newswire
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.
Zacks
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.
Zacks
Madrigal Pharmaceuticals Q1 Earnings Call Highlights
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported first-quarter 2026 net sales of $311.3 million as executives said demand for its MASH therapy Rezdiffra continued to build in a market they described as still early in development. On the company's earnings call, management highlighted patient growth...
MarketBeat
<
1
2
>

Advertisement|Remove ads.